COMMUNIQUÉS West-GlobeNewswire

Cancer and Blood Specialists of Georgia Opens New Oncology Clinic in Cumming
06/02/2024
The community oncology practice is equipped to treat a wide variety of cancer types and is open to both new and current patients. CUMMING, Ga., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cancer and Blood Specialists of Georgia [...]
Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
06/02/2024
CAMBRIDGE, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
06/02/2024
NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by [...]
NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under “SCPX” Effective at the Market Open Today
06/02/2024
DURHAM, N.C., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences / Scorpius Holdings, Inc. (NYSE American: NHWK ; SCPX) , an integrated contract development and manufacturing organization (CDMO), today announced [...]
Alignment Healthcare to Announce Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call Tuesday, Feb. 27, 2024
06/02/2024
ORANGE, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), will release its fourth quarter and full-year 2023 financial results on Tuesday, Feb. 27, after market close. Following the [...]
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss
06/02/2024
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today [...]
electroCore Expands Intellectual Property Portfolio
06/02/2024
ROCKAWAY, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has [...]
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
06/02/2024
-- Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC ® ) protein degrader designed to target and degrade the estrogen receptor (ER) protein -- NEW HAVEN, Conn. and NEW YORK, Feb. 06, 2024 (GLOBE [...]
PEAR Health Labs partners with Google Cloud to enhance personalized fitness experience with generative AI
06/02/2024
Two leading artificial intelligence companies collaborate to lower barriers to accessing personalized health and fitness recommendations with a more approachable, interactive digital interface SOLANA BEACH, Calif., Feb [...]
Curium Announces Ioflupane I 123 Injection Availability for Friday Patient Use
06/02/2024
ST. LOUIS, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that beginning Friday, April 5, 2024, Ioflupane I 123 Injection will be available for Friday patient [...]
Novo Nordisk A/S - share repurchase programme
06/02/2024
Bagsværd, Denmark, 6 February 2024 – The execution of Novo Nordisk A/S’ overall share repurchase programme for 2024 of DKK 20 billion will be initiated on 6 February 2024. As part of this, Novo Nordisk A/S has now [...]
Nicox announces presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024
06/02/2024
Press Release Nicox announces presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024 February 6, 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA ( [...]
Nicox : Présentations au prochain Congrès Annuel 2024 de l’Association for Research in Vision and Ophthalmology (ARVO)
06/02/2024
Communiqué de presse Nicox : Présentations au prochain Congrès Annuel 2024 de l’Association for Research in Vision and Ophthalmology (ARVO) 6 février 2024 – diffusion à 7h30 Sophia Antipolis, France Nicox SA (Euronext [...]
Mithra updates on cash position
06/02/2024
Mithra updates on cash position Mithra's current cash of EUR 6.5 million is expected to cover its current cash runway through early March Mithra is actively engaging with stakeholders Mithra will present its results for [...]
Mithra updates on cash position
06/02/2024
Mithra updates on cash position Mithra's current cash of EUR 6.5 million is expected to cover its current cash runway through early March Mithra is actively engaging with stakeholders Mithra will present its results for [...]
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
06/02/2024
LOS ANGELES, CA, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and [...]
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash
05/02/2024
Transaction to include pelabresib, a late-stage BET inhibitor for myelofibrosis (MF) and tulmimetostat, an early-stage investigational dual inhibitor of EZH2 and EZH1 for solid tumors or lymphomas Pelabresib recently [...]
Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Initial Business Combination to March 3, 2024
05/02/2024
MIAMI, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “ Company ”) a special purpose acquisition company, announced today that on February 1, 2024, its sponsor, [...]
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/02/2024
DUBLIN, Ireland, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to [...]

Pages